Penn Cardiovascular Institute

Reilly Group

Contact the Lab

Muredach P. Reilly, MBBCH, MSCE

Muredach P. Reilly
Principal Investigator

Muredach P. Reilly, MBBCH, MSCE
University of Pennsylvania
11-136 Smilow Center for Translational Research
3400 Civic Center Boulevard, Bldg. 421
Philadelphia, PA 19104
215-573-1214
muredach@mail.med.upenn.edu

Christine Hinkle, MSC
(Lab Manager)
University of Pennsylvania
11-170 Smilow Center for Translational Research
3400 Civic Center Blvd., Bldg. 421
Philadelphia, PA 19104
215-573-0244
chinkle@mail.med.upenn.edu

 

Overview

The Reilly Group at the University of Pennsylvania is dedicated to translational and genomic studies in human cardio-metabolic disorders. With expertise in preclinical cell and rodent models, human cardio-metabolic disease, as well as human genomics and epidemiology, the group is comprised of wet-lab, computational, and clinical scientists and is integrated across the spectrum of clinical to basic activities and is particularly focused on applying novel technologies in defining the mechanisms of complex cardiovascular disorders.

Currently funded projects include:

  • Rodent and human gain-of-function and loss-of-function in modeling genes/pathways in atherosclerosis and insulin resistance, (e.g., metalloproteianses, chemokines)
  • Applications of RNA-seq in humans(e.g., tissue- and cell-specific RNA modulation in human inflammation)
  • Unbiased glycomics in heart disorders, extensions of GWAS and exome-sequencing in coronary atherosclerosis (e.g., ADAMTS7)
  • Epidemiology and clinical trials in humans (e.g., heart disease in kidney disease)
  • Novel analytic methods for our high-dimensional data.

Doctor Reilly is also committed to mentoring young scientists in mechanistic translational research in complex human cardiometabolic disorders.

  • The Reilly group uses human discoveries to identify new mechanisms and treatment targets for heart disease.
  • The Reilly applies GWAS, DNAseq and RNAseq in searching for new genes and pathways in heart disease.
  • Using stem cells to study genetic mechanisms in human heart disease: Endothelial cells generated from human induced pluripotent stem cells (hIPSC).

Research Projects

Elucidation of Tissue-Specific Transcriptomic Profiles in Cardiometabolic Disease
Funding:
R01-HL-113147 (NIH/NHLBI) (PI: Reilly) 4/16/12 to 3/31/16
Penn Genome Frontiers Institute Pilot Award (PI: Reilly) 7/1/10 to 6/30/13
Goals:
Translational genomic studies to apply deep RNA sequencing of human tissue and cells to identify novel transcriptomic variations and mechanisms of tissue-specific genetic dysfunction in cardio-metabolic disease.
Translational Studies of ADAMTS7 a Novel GWAS Locus for Coronary Atherosclerosis
Funding:
R01-HL-111694 (NIH/NHLBI) (PI: Reilly) 7/19/12 to 6/30/16

ADAMTS7 a is a gene for human atherosclerosis

Goals:
Functional genomics of a locus for human coronary atherosclerosis. Define structure-function of ADAMTS7 interactions with target proteins, assess the effects of loss function and gain of function on mouse atherosclerosis and VSMC function, and interrogate non-synonymous variants discovered upon sequencing of ADAMTS7 in humans for potential loss and gain of function and for association with CAD.
Glycomics of Heart and Lung Disease in the Genomic Era
Funding:
U01-HL108636 (NIH/NHLBI) (PI: Reilly) 8/20/11 to 6/30/15

Unbiased glycomics in discovery of cell specific mechanisms in human heart disease

Goals:
Translational studies in human of locus for human myocardial infarction and cardiometabolic traits. Using unbiased mass-spectrometry approaches, we propose to define disease (myocardial infarction and acute lung injury) and cell (platelets and endothelium) specific ABO glycoproteomes in order to develop causal glycopeptides markers of risk and cross-organ, mechanisms-based phenotypes in heart and lung disease.
Fractalkine in Adipose Inflammation and Insulin Resistance
Funding:
R01-DK-090505 (NIH/NIDDK) (PI: Reilly) 7/19/11 to 5/31/16
Goals:
Using mice models and human translation, we aim to determine whether fractalkine (CX3CL1-CX3CR1) has independent and/or synergistic actions with CCR2 and CCR5 chemokine pathways in modulating adipose inflammation and its metabolic consequences.
Methods for High-Dimensional Data in Cardiovascular Research
Funding:
R01-HL107196-06A1 (NIH/NHLBI ) (PI: Foulkes) 2/3/11 to 1/31/16
Other collaborative R01's (e.g., with Mingyao Li PhD)
Goals:
Develop and apply methods for characterizing the relationship between human genomic data and human complex phenotypes.
Mentored Translational Research in Cardio-metabolic Disease
Funding:
K24-HL107643 (NIH/NHLBI) (PI: Reilly) 5/13/11 to 4/30/16
Goals:
To support mechanistic translational and clinical research mentoring, to provide increased time and structure in mentoring young investigators, and to pursue innovative research strategies in training a new generation of leaders in translational research.

Members

  • Rachana Shah, MD
  • Jane Ferguson, PhD
  • Sean O'Neill, PhD, MBA
  • Hanrui Zhang, MD, PhD
  • Xuan Zhang, PhD
  • Robert Bauer, PhD
  • Jackie Serfecz, MSc
  • Chenyi Xue, MSc
  • Liming Qu, MS
  • Rhia Shah, BA
  • Jian Cui, MD
  • Christine Hinkle, MSc
    Lab Manager
  • Jennifer Tabita-Martinez, BSc
    Clinical coordinator
  • Karen Terembula, BSc
    Clinical coordinator
  • Raoul Bhatta, MD
  • Tramel Parker
    Administrative assistant
  • Gayle Meadows
    Grant Manager

Selected Publications

To Top